Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04350138
Recruitment Status : Recruiting
First Posted : April 16, 2020
Last Update Posted : June 21, 2022
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participants are expected to be enrolled to achieve at least 202 evaluable participants. Data will be collected in an observer-blind manner. Study product recipients and study staff responsible for the evaluation of any study endpoint will be unaware of whether Bexsero or placebo were administered. The duration of the study for participants who are enrolled and randomized will be approximately 16 months. Study participation is expected to be completed in approximately 36 months. The primary objective of the study is to demonstrate efficacy of Bexsero in prevention of urogenital and/or anorectal gonococcal infection.

Condition or disease Intervention/treatment Phase
Gonococcal Infection Biological: Meningococcal Group B Vaccine Other: Placebo Phase 2

Detailed Description:
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participants are expected to be enrolled to achieve at least 202 evaluable participants. Data will be collected in an observer-blind manner. Study product recipients and study staff responsible for the evaluation of any study endpoint will be unaware of whether Bexsero or placebo were administered. Participants who consent to screening will have baseline clinical information collected at Visit 0, Screening (Day -14 [Window -45 to -7]). This information will consist of medical history, concomitant medications, physical exam, sexual history, and clinical and laboratory findings. Participants will undergo a physical exam and have blood drawn to establish baseline laboratory values for safety assessment. Urine or a vaginal swab, and a rectal swab will be collected for Nucleic Acid Amplification Test (NAAT) for gonorrhea and chlamydia. A pharyngeal swab will be collected for NAAT testing of gonorrhea. At the enrollment visit, Visit 1, participants who test negative for gonorrhea and who otherwise qualify will be enrolled and randomized in a 1:1 ratio to receive the initial intramuscular (IM) dose of study product. A phone call, Visit 2, will be held approximately 30 days after the initial study product dose was received and will be conducted with all participants to assess for safety events in the interim. At Visit 3, the participant will receive the second dose of study product. Visit 4 will be held 1 month after second dose. At 3-month intervals, through the final study follow-up visit, participants will have clinic study visits, Visit 5 thru Visit 8. The duration of the study for participants who are enrolled and randomized will be approximately 16 months. For those not enrolled, participation could end at their Visit 0, Screening; post Visit 0, Screening based on NAAT test results; or Visit 1, Enrollment. Study participation is expected to be completed in approximately 36 months. The primary objective of the study is to demonstrate efficacy of Bexsero in prevention of urogenital and/or anorectal gonococcal infection. The secondary objectives are to estimate efficacy of Bexsero in prevention of overall gonococcal infection and by anatomical site (urogenital, anorectal or pharyngeal) and to assess safety of Bexsero.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase II Randomized, Observer-Blind, Placebo-Controlled Study, to Assess the Efficacy of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) in Preventing Gonococcal Infection
Actual Study Start Date : December 29, 2020
Estimated Primary Completion Date : August 1, 2023
Estimated Study Completion Date : August 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Gonorrhea Vaccines

Arm Intervention/treatment
Experimental: Group 1
Bexsero vaccine will be administered as an intramuscular injection in 1 mL single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
Biological: Meningococcal Group B Vaccine
A combination vaccine consisting of rMenB and OMV NZ.

Placebo Comparator: Group 2
Placebo will be administered as an intramuscular injection in single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
Other: Placebo
150mM sodium chloride (0.9% saline solution).




Primary Outcome Measures :
  1. Number of participants diagnosed with urogenital or anorectal gonococcal infection post second vaccination [ Time Frame: Day 91 to Day 451 ]
    Confirmed by Nucleic Acid Amplification Test (NAAT).


Secondary Outcome Measures :
  1. Number of participants diagnosed with urogenital, anorectal, or pharyngeal gonococcal infection post second vaccination [ Time Frame: Day 91 to Day 451 ]
    Confirmed by Nucleic Acid Amplification Test (NAAT).

  2. Proportion of participants that experience at least one adverse event (AE) that results in withdrawal from study [ Time Frame: Day 1 to Day 451 ]
    Disease or medical condition, or new clinical finding(s) for which continued participation, in the opinion of the investigator might compromise the safety of the participant, interfere with the participant's successful completion of this study, or interfere with the evaluation of study endpoints.

  3. Proportion of participants that experience at least one adverse event of special interest (AESI) [ Time Frame: Day 1 to Day 451 ]
    Adverse Event of Special Interest (AESI) are specific to the protocol: Arthritis, Potential immune-mediated diseases (pIMD).

  4. Proportion of participants that experience at least one serious adverse event (SAE) [ Time Frame: Day 1 to Day 451 ]
  5. Proportion of participants with at least one medically attended adverse event (MAAE) [ Time Frame: Day 1 to Day 451 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Participants aged 18 to 50 years of age inclusive on the day of enrollment;
  2. If female, participant must be of non-childbearing potential* or has a negative pregnancy test prior to each vaccination**.

    *Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopausal (no menses for at least 12 months);

    **Note: Although contraceptive methods are not mandated since Bexsero is a marketed product and will be used according to the label, it is anticipated that contraceptive counselling will be provided according to local standard of care.

  3. Participant is in good health as determined by past medical history, medication use, and targeted physical examination (including vital signs), in opinion of investigator or their delegate;
  4. Has provided signed informed consent;
  5. Willing and likely to comply with the trial procedures;
  6. Is prepared to grant authorized persons access to the study's medical records.

Exclusion Criteria:

  1. Previous receipt of a Meningococcal Group B vaccine;
  2. Gonorrhea or chlamydia infection identified by a positive nucleic acid amplification test (NAAT) within 14 days prior to randomization;
  3. Receipt of antibiotics active against N. gonorrhoeae in the prior 14 days, including oral or parenteral antibiotics;
  4. Progressive, unstable, or uncontrolled disease including but not limited to cardiac, hepatic, renal, immunological, neurological or psychiatric conditions;
  5. Use of any investigational drug (with the exception of an authorized or approved COVID-19 vaccine) within 30 days prior to enrollment, or planned/anticipated use during study participation;
  6. Has received or plans to receive a live vaccine within +/- 30 days, an inactive vaccine within +/- 14 days, or an influenza vaccine within +/- 7 days from receipt of study product;*

    *Authorized or approved, inactivated COVID-19 vaccines may be given more than 7 days +/- receipt of study product for all study participants.

  7. Currently receiving immunosuppressive agent or systemic corticosteroid (dose >/=5 mg/day of prednisone) for > 14 consecutive days within 90 days prior to enrollment*;

    *Topical or inhaled steroids allowed, unless applied to study project injection site.

  8. Has received antineoplastic, or radiotherapy within 90 days prior to enrollment;
  9. Has received immunoglobulins and/or any blood products within 180 days prior to enrollment;
  10. Known or confirmed hypersensitivity to any of the vaccine constituents, latex, medical products, or medical equipment whose use is foreseen in this study;
  11. HIV-infected participants with CD4 cell count < 300 cells/mm3 in the last year;
  12. Has a condition which in the opinion of the investigator is not suitable for intramuscular vaccination, blood draws, or participation in the trial;
  13. Participant is breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04350138


Contacts
Layout table for location contacts
Contact: Jeanne M. Marrazzo 12059755500 jmarrazzo@uabmc.edu

Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham School of Medicine - Infectious Disease Recruiting
Birmingham, Alabama, United States, 35294
United States, California
UCLA Clinical AIDS Research and Education (CARE) Center Recruiting
Los Angeles, California, United States, 90035
SFDPH Bridge HIV Center Not yet recruiting
San Francisco, California, United States, 94102
United States, Georgia
Emory University Hospital Midtown - Emory Clinic Infectious Diseases Recruiting
Atlanta, Georgia, United States, 30308
United States, Indiana
Indiana University School of Medicine - Infectious Diseases Not yet recruiting
Indianapolis, Indiana, United States, 46202
United States, Louisiana
LSU - CrescentCare Sexual Health Center Recruiting
New Orleans, Louisiana, United States, 70119
United States, Maryland
Walter Reed National Military Medical Center Recruiting
Bethesda, Maryland, United States, 20889
Thailand
The Thai Red Cross AIDS Research Centre Recruiting
Bangkok, Thailand, 10330
Armed Forces Research Institute of Medical Sciences - Royal Thai Army Clinical Research Center Recruiting
Bangkok, Thailand, 10400
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT04350138    
Other Study ID Numbers: 19-0004
First Posted: April 16, 2020    Key Record Dates
Last Update Posted: June 21, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Bexsero
Gonococcal infection
Meningococcal Group B Vaccine rMenB+OMV NZ
Observer-blind
Phase 2
Placebo-controlled study
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
Gonorrhea
Disease Attributes
Pathologic Processes
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Sexually Transmitted Diseases, Bacterial
Sexually Transmitted Diseases